ARC International (LSE:ARK) announced that CVRx(R), Inc. has chosen a member of the configurable ARC(R) 600 core family to drive its Rheos(TM) Baroreflex Hypertension Therapy(TM) System. CVRx chose a configurable ARC core because of its very small size, ability to operate using extremely low power, and long-term reliability – all key criteria for “deeply embedded” organic applications.
Hypertension (high blood pressure) is an excessive force of blood against arterial walls. It is a leading cause of heart and kidney disease, stroke, and premature death. According to the American Heart Association, close to 70 million people in the United States suffer from high blood pressure. Approximately 25 percent cannot control the disease despite the use of multiple medications.
The Rheos System from CVRx reduces blood pressure by using the human body’s natural blood pressure regulation system (the baroreflex). The Rheos System electrically stimulates the baroreflex, which sends signals to the brain suggesting a blood pressure increase. Then, the brain acts to lower blood pressure by sending signals to various parts of the body, including the blood vessels, heart and kidneys. The Rheos System includes a small pulse generator that is implanted under the collar bone, two thin leads that are wrapped around the left and right carotid arteries, and a programmer system.
“The Rheos System holds hope for patients with drug-resistant hypertension,” said Nadim Yared, president and CEO of CVRx. “By adopting a configurable ARC processor our development teams can ensure the implantable, battery operated Rheos System meets important criteria necessary for implantable medical devices.”
Andy Jaros, vice president of worldwide field operations for ARC, said, “For years ARC’s configurable processors have been broadly used in a wide range of medical products. From pacemakers to hearing aids, ARC’s low power configurable solutions are being adopted to create innovative next-generation medical technologies. Products such as the Rheos System from one of ARC’s newest customers could have a beneficial impact on the health and life expectancy of millions of individuals worldwide.”
About CVRx, Inc.
CVRx was founded in 2001 and is headquartered in Minneapolis. It is a private company and its senior management and technical teams have many years of experience commercializing implantable medical devices.
About ARC International plc
ARC International is the world leader in configurable media subsystems and CPU/DSP processors. Used by over 140 companies worldwide, ARC’s configurable solutions enable the creation of highly differentiated system-on-chips (SoCs) that ship in hundreds of millions of devices annually. ARC’s patented subsystems and cores are smaller, consume less power, and are less expensive to manufacture than competing products. ARC International maintains a worldwide presence with corporate and research and development offices in California and St. Albans, UK. ARC International is listed on the London Stock Exchange as ARC International plc (LSE:ARK).
ARC and the ARC logo are trademarks or registered trademarks of ARC International.